Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with stable coronary artery disease, it remains unclear whether an initial management strategy of percutaneous coronary intervention (PCI) with intensive pharmacologic therapy and lifestyle intervention (optimal medical therapy) is superior to optimal medical therapy alone in reducing the risk of cardiovascular events. METHODS: We conducted a randomized trial involving 2287 patients who had objective evidence of myocardial ischemia and significant coronary artery disease at 50 U.S. and Canadian centers. Between 1999 and 2004, we assigned 1149 patients to undergo PCI with optimal medical therapy (PCI group) and 1138 to receive optimal medical therapy alone (medical-therapy group). The primary outcome was death from any cause and nonfatal myocardial infarction during a follow-up period of 2.5 to 7.0 years (median, 4.6). RESULTS: There were 211 primary events in the PCI group and 202 events in the medical-therapy group. The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (hazard ratio for the PCI group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%; hazard ratio, 1.07; 95% CI, 0.84 to 1.37; P=0.56); or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). CONCLUSIONS: As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy. (ClinicalTrials.gov number, NCT00007657 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended (Fig. 10.5), in part because these high-risk people should already be receiving intensive medical therapy-an approach that provides benefits similar to those of invasive revascularization (208,209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“The screening of asymptomatic individuals with high ASCVD risk is not recommended, in part because these high-risk people should already be receiving intensive medical therapy—an approach that provides benefits similar to those of invasive revascularization (197,198).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [197]
In the citing paper
“OMT with risk modification remains the foundation of management in patients with T2DM and CAD.263,264”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [264]
In the citing paper
“these high-risk patients should already be receiving intensive medical therapy -an approach that provides benefi t similar to invasive revascularization (172,173).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [172]
In the citing paper
“The screening of asymptomatic patients remains controversial, especially as intensive medical therapy indicated in diabetic patients at high risk for CVD has an increasing evidence base for providing equal outcomes to invasive revascularization, including in diabetic patients (222).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [222]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Self-citationThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12113-7 · Cited by 4,361
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
Cited by
Items 801–900 of 1,002
Rabbat, M., Leipsic, J. A., Bax, J. J., Kauh, B., Verma, R., Doukas, D. G., Allen, S., Pontone, G., Wilber, D. J., Mathew, V., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020604 · Cited by 37
Greenwood, B. N., Agarwal, R., Agarwal, R., & Gopal, A. (2017) · Management Sciences · doi:10.1287/mnsc.2016.2490 · Cited by 30
“The clinical trial, which supported the contents of the guideline, was released later, i.e., the COURAGE trial (Boden et al. 2007).”
Becker, L. M., Peper, J., Verhappen, B. J. L. A., Swart, L. A., Dedic, A., van Dockum, W. G., van der Ent, M., Royaards, K., Niezen, A., Hensen, J.-H. J., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09517-z · Cited by 41
Liu, B., Han, M., & Wen, J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127407 · Cited by 37
“However, its overall benefits are limited by the fact that it may induce local arterial restenosis in many patients who are initially treated successfully (Bennett and Schwartz, 1995; Boden et al., 2007).”
BackgroundComment on the Reports of Over-estimation of ASCVD Risk Using the 2013 AHA/ACC Risk Equation
Muntner, P., Safford, M. M., Cushman, M., & Howard, G. (2013) · Circulation · doi:10.1161/circulationaha.113.007648 · Cited by 41
A contemporary review of sudden cardiac arrest and death in competitive and recreational athletes
Kim, J. H., Martinez, M. W., Guseh, J. S., Krishnan, S., Gray, B. R., Harmon, K. G., Papadakis, M., Phelan, D. M. J., Stewart, K., Levine, B. D., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02086-5 · Cited by 47
Kertai, M. D. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31816072b3 · Cited by 36
Pontone, G., Andreini, D., Baggiano, A., Bertella, E., Mushtaq, S., Conte, E., Beltrama, V., Guaricci, A. I., & Pepi, M. (2015) · BioMed Research International · doi:10.1155/2015/297696 · Cited by 36
“Indeed, the Clinical Outcome Utilizing Revascularization and Aggressive Drug Evaluation trial (COURAGE) [3] and the COURAGE trial nuclear substudy [4] have demonstrated that the event-free survival with coronary revascularization was greater than optimal medical therapy in patients with ≥10% ischemic myocardium at bas…”
MethodPercutaneous Coronary Intervention Should Be Guided by Fractional Flow Reserve Measurement
Fearon, W. F. (2014) · Circulation · doi:10.1161/circulationaha.113.004300 · Cited by 36
Do Medicare Advantage plans select enrollees in higher margin clinical categories?
Newhouse, J. P., McWilliams, J. M., Price, M., Huang, J., Fireman, B. H., & Hsu, J. (2013) · Journal of Health Economics · doi:10.1016/j.jhealeco.2013.09.003 · Cited by 36
EXAMINATION of new drug-eluting stents—top of the class!
Bhatt, D. L. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61021-6 · Cited by 36
Hughes, J., Kee, F., O’Flaherty, M., Critchley, J., Cupples, M., Capewell, S., & Bennett, K. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312441725 · Cited by 42
Lipoprotein Disorders and Cardiovascular Disease
Genest, J. J., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00047-0 · Cited by 38
Aortic stiffness improves the prediction of both diagnosis and severity of coronary artery disease
Yannoutsos, A., Ahouah, M., Dreyfuss-Tubiana, C., Topouchian, J. A., Safar, M. E., & Blacher, J. (2017) · Hypertension Research · doi:10.1038/hr.2017.97 · Cited by 38
Guo, M. H., Wang, P., Du, J., Fu, C., Yang, Q., Gao, Z., Zhu, M., Lv, S., Deng, Y., Li, T., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104883 · Cited by 36
Guo, L., Wang, J., Ding, H., Meng, S., Zhang, X., Lv, H., Zhong, L., Wu, J., Xu, J., Zhou, X., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01087-4 · Cited by 38
Basis for use of central blood pressure measurement in office clinical practice
O’Rourke, M. F., & Adji, A. I. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.08.006 · Cited by 37
The impact of revascularization on myocardial blood flow as assessed by positron emission tomography
Bober, R., Milani, R. V., Oktay, A. A., Javed, F., Polin, N. M., & Morin, D. P. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04278-8 · Cited by 36
Diabetes with Coronary Disease — A Moving Target amid Evolving Therapies?
Boden, W. E., & Taggart, D. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0904090 · Cited by 36
Self-citationFezzi, S., Ding, D., Mahfoud, F., Huang, J., Lansky, A., Tu, S.-X., & Wijns, W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01014-0 · Cited by 33
Achievement of Optimal Medical Therapy Goals for U.S. Adults With Coronary Artery Disease
Brown, T. M., Voeks, J. H., Bittner, V., Brenner, D. A., Cushman, M., Goff, D. C., Glasser, S. P., Muntner, P., Tabereaux, P. B., & Safford, M. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.042 · Cited by 35
Borràs, X., García–Moll, X., Gómez‐Doblas, J. J., Zapata, A., & Artigas, R. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.03.011 · Cited by 35
Ketterer, M. W., Knysz, W., Keteyian, S. J., Schairer, J. R., Jafri, S. M., Alam, M., Farha, A., & Deveshwar, S. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.3.230 · Cited by 35
Song, Y. B., Lee, S. Y., Hahn, J., Choi, S., Choi, J., Lee, S. H., Hong, K. P., Park, J. E., & Gwon, H. (2011) · Heart and Vessels · doi:10.1007/s00380-011-0173-x · Cited by 37
Trends in PCI Volume after Negative Results from the COURAGE Trial
Howard, D. H., & Shen, Y. (2013) · Health Services Research · doi:10.1111/1475-6773.12082 · Cited by 35
“The study, which was published in April 2007 in the New England Journal of Medicine (Boden et al. 2007), found that the treatments were equivalent in terms of survival time and heart attack risk.”
BackgroundMethodInfluentialRecent Changes in Practice of Elective Percutaneous Coronary Intervention for Stable Angina
Ahmed, B., Dauerman, H. L., Piper, W. D., Robb, J. F., Verlee, M. P., Ryan, T. J., Goldberg, D. J., Boss, R. A., Phillips, W. J., Fedele, F. A., et al. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957175 · Cited by 35
Maroney, J., Khan, S. B., Powell, W., & Klein, L. W. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24366 · Cited by 35
“) [4,5], as well as reduced rates of in-stent restenosis with the increasing usage of drugeluting stents, and longer periods of dual antiplatelet drug therapy after PCI.”
BackgroundMeinel, F. G., Ebersberger, U., Schoepf, U. J., Lo, G. G., Choe, Y. H., Wang, Y., Maivelett, J., Krazinski, A. W., Marcus, R. P., Bamberg, F., et al. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.13.12328 · Cited by 35
The Future of Periodontal-Systemic Associations: Raising the Standards
Bartold, P. M., & Mariotti, A. J. (2017) · Current Oral Health Reports · doi:10.1007/s40496-017-0150-2 · Cited by 35
Han, S., Park, G., Kim, Y., Park, M., Her, S., Lee, S., & Kim, Y. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2017.0359 · Cited by 35
Kawase, Y., Matsuo, H., Akasaka, T., Shiono, Y., Tanaka, N., Amano, T., Kozuma, K., Nakamura, M., Yokoi, H., Kobayashi, Y., et al. (2018) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-018-0559-0 · Cited by 35
Weintraub, W. S., Hartigan, P. M., Mancini, G. B. J., Teo, K. K., Maron, D. J., Spertus, J. A., CHAITMAN, B. R., Shaw, L. J., Berman, D. S., Boden, W. E., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005079 · Cited by 35
Self-citationIntensive Cardiac Rehabilitation: an Underutilized Resource
Freeman, A. M., Taub, P. R., Lo, H. C., & Ornish, D. M. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1104-1 · Cited by 36
Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms
Vallée, A., Cinaud, A., Protogerou, A. D., Zhang, Y., Topouchian, J. A., Safar, M. E., & Blacher, J. (2020) · Current Hypertension Reports · doi:10.1007/s11906-019-1006-z · Cited by 36
Percutaneous Coronary Intervention in Stable Coronary Heart Disease —Is Less More?
Figulla, H. R., Lauten, A., Maier, L. S., Sechtem, U. P., Silber, S., & Thiele, H. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0137 · Cited by 49
“Moreover, the two treatment groups had the same overall mortality, which, in turn, was nearly the same as that of the ageand sex-matched normal population (Figure 3) (24, 25).”
BackgroundResultMadhavan, M. V., Redfors, B., Ali, Z. A., Prasad, M., Shahim, B., Smits, P. C., von Birgelen, C., Zhang, Z., Mehran, R., Serruys, P. W. J. C., et al. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008565 · Cited by 39
Percutaneous coronary intervention in nonagenarians: pros and cons.
Biondi‐Zoccai, G., Abbate, A., D’Ascenzo, F., Presutti, D. G., Peruzzi, M., Cavarretta, E., Marullo, A. G. M., Lotrionte, M., & Frati, G. (2013) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2013.01.013 · Cited by 36
Boden, W. E., Finn, A. V., Patel, D. D., Peacock, W. F., Thadani, U., & Zimmerman, F. H. (2012) · Clinical Cardiology · doi:10.1002/clc.21993 · Cited by 38
Self-citationNair, S. U., Ahlberg, A. W., Mathur, S., Katten, D. M., Polk, D. M., & Heller, G. V. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9477-6 · Cited by 34
In-hospital peak glycemia and prognosis in STEMI patients without earlier known diabetes
Lazzeri, C., Valente, S., Chiostri, M., Picariello, C., & Franco, G. G. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328335f26f · Cited by 39
Kaski, J. C., & Consuegra‐Sánchez, L. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827656 · Cited by 35
Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006
Rastam, S., Ali, R. A., Maziak, W., Mzayek, F., Fouad, F. M., O’Flaherty, M., & Capewell, S. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-754 · Cited by 37
“Data were based on the results of recent meta-analyses and randomised controlled trials [22-52].”
MethodPET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand
Wan, M. Y. S., Endozo, R., Michopoulou, S. K., Shortman, R. I., Rodriguez‐Justo, M., Menezes, L., Yusuf, S. W., Richards, T., Wild, D., Waser, B., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181438 · Cited by 36
Which Is More Enduring — FAME or COURAGE?
Boden, W. E. (2012) · New England Journal of Medicine · doi:10.1056/nejme1208620 · Cited by 35
Self-citationPercutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?
Tamburino, C., Capranzano, P., Capodanno, D., Dangas, G., Zimarino, M., Bass, T. A., Mehran, R., Antoniucci, D., Colombo, A., Manna, A. L., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.10.017 · Cited by 34
“Regarding pharmacotherapy, details on medications have been rarely reported, and therefore, assessment of the proportion of patients taking guideline-based optimal medical therapy, which may provide comparable rates of mortality and MI compared with PCI in stable patients, is unknown.(45) Also, the ischemic burden, wh…”
ResultPeriprocedural Myocardial Infarction: Review and Classification
Hanna, E. B., & Hennebry, T. A. (2010) · Clinical Cardiology · doi:10.1002/clc.20819 · Cited by 39
Abe, M., Kimura, T., Morimoto, T., Furukawa, Y., & Kita, T. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0784 · Cited by 36
Shaw, L. J., Min, J. K., Hachamovitch, R., Hendel, R. C., Borges‐Neto, S., & Berman, D. S. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9468-7 · Cited by 34
“Although variability in high risk status has been reported, a threshold of 5%-10% per year for CAD death or MI is commonly applied for stable CAD patients at elevated and high risk status.(23) Using these thresholds, for exercising patients with a preserved resting LVEF, then those with moderatesevere ischemia would w…”
BackgroundSelf-citationIt is not yet the time to stop screening diabetic patients for silent myocardial ischaemia
Valensi, P. E., & Cosson, E. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.01.001 · Cited by 34
Is This Time Different?: The Slowdown in Health Care Spending
Chandra, A., Holmes, J. M., & Skinner, J. (2013) · Brookings Papers on Economic Activity · doi:10.1353/eca.2013.0014 · Cited by 46
“During the mid2000s, however, several randomized trials suggested very modest benefits arising from the use of stents for the most common types of heart disease (e.g., Boden et al., 2007), leading to a downturn in the use of these procedures.”
BackgroundTan, X., Shi, J., & Chen, A. M.-H. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0310-7 · Cited by 41
“Certain studies have mentioned that the difference in optimal use of medications at follow-up among the subgroups with a high body mass index (BMI) when compared to patients with normal weight, has also partly contributed to this obesity paradox [5–7].”
BackgroundA meta-analysis update: percutaneous coronary interventions.
Cecil, W. T., Kasteridis, P., Barnes, J. W., Mathis, R. S., PATRIC, K. D., & Martin, S. (2008) · PubMed · Cited by 37
Singh, M., Peterson, E. D., Milford–Beland, S., Rumsfeld, J. S., & Spertus, J. A. (2008) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.107.755991 · Cited by 34
Self-citationTrends in Coronary Revascularization and Ischemic Heart Disease–Related Mortality in Israel
Blumenfeld, O., Na’amnih, W., Shapira‐Daniels, A., Lotan, C., Shohat, T., & Shapira, O. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004734 · Cited by 34
Hiraya, D., Sato, A., Hoshi, T., Watabe, H., Yoshida, K., Komatsu, Y., Sekiguchi, Y., Nogami, A., Ieda, M., & Aonuma, K. (2019) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14029 · Cited by 35
A pathophysiological compass to personalize antianginal drug treatment
Bertero, E., Heusch, G., Münzel, T. F., & Maack, C. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00573-w · Cited by 38
Mehta, S. R., Wang, J., Wood, D. A., Spertus, J. A., Cohen, D. J., Mehran, R., Storey, R. F., Steg, P. G., Pinilla‐Echeverri, N., Sheth, T., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3032 · Cited by 34
Self-citationUeng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Cardiac PET: Metabolic and Functional Imaging of the Myocardium
Ardle, B. M., Dowsley, T. F., Cocker, M. S., Ohira, H., deKemp, R. A., DaSilva, J. N., Ruddy, T. D., Chow, B. J. W., & Beanlands, R. S. (2013) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2013.06.001 · Cited by 35
A Clinical Model to Identify Patients With High-Risk Coronary Artery Disease
Yang, Y., Chen, L., Yam, Y., Achenbach, S. S., Al-Mallah, M. H., Berman, D. S., Budoff, M. J., Cademartiri, F., Callister, T. Q., Chang, H., et al. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.11.015 · Cited by 34
“The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared outcomes of non–high-risk CAD patients treated with medical therapy or with percutaneous coronary intervention coupled with medical therapy and concluded that revascularization did not significantly reduce mortali…”
InfluentialSelf-citationPerspectives on the management of coronary artery disease in India
Karthikeyan, G., Xavier, D., Prabhakaran, D., & Pais, P. (2007) · Heart · doi:10.1136/hrt.2007.131193 · Cited by 34
“This information represents data collated from the 109 participating hospitals in the National Registry of Coronary Interventions. The number of procedures is likely to be larger, as a considerable number of small PCI-capable centres are not represented in the registry. In the absence of national guidelines, the indic…”
Percutaneous Coronary Interventions in the Diabetic Patient: Where Do We Stand?
Bittl, J. A. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001944 · Cited by 36
Shen, Y., & Hsia, R. Y.-J. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1462 · Cited by 34
Yonetsu, T., Murai, T., Kanaji, Y., Lee, T., Matsuda, J., Usui, E., Hoshino, M., Araki, M., Niida, T., Hada, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005916 · Cited by 34
“However, FFR evaluation is still underutilized; instead, coronary angiography is widely used as a gatekeeper for decisionmaking of revascularization even in large clinical trials.(2,12) Subanalysis of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) trial has shown that angiography is i…”
MethodMancini, G. B. J., Maron, D. J., Hartigan, P. M., Spertus, J. A., Kostuk, W. J., Berman, D. S., Teo, K. K., Weintraub, W. S., & Boden, W. E. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.067 · Cited by 33
Self-citationMyocardial Infarction in Heart Failure With Preserved Ejection Fraction
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.02.007 · Cited by 33
Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome
Buntaine, A. J., Shah, B., Lorin, J. D., & Sedlis, S. P. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0756-3 · Cited by 34
Boden, W. E., Caterina, R. D., Kaski, J. C., Merz, C. N. B., Berry, C., Marzilli, M., Pepine, C. J., Barbato, E., Stefanini, G. G., Prescott, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065656 · Cited by 39
Self-citationDiabetes mellitus and the heart
Mercer, B. N., Morais, S. R. D. L. O. K., Cubbon, R. M., & Kearney, M. T. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02924.x · Cited by 37
The prognostic value of cardiac SPECT performed at the primary care physician’s office
Doukky, R., Frogge, N., Balakrishnan, G., Hayes, K., Collado, F., Rangel, M. O., Trohman, R. G., & Hendel, R. C. (2013) · Journal of Nuclear Cardiology · doi:10.1007/s12350-013-9676-4 · Cited by 32
Diabetes and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0007 · Cited by 39
“Similar conclusions can be drawn from the Clinical Outcomes Using Revascularization and Aggressive Drug Evaluation (COURAGE) trial, in which 33% of enrolled patients had diabetes (51) and BARI-2D (discussed above), leading Standl to conclude that individuals with diabetes are still at high CAD risk (around 15–20% at 1…”
ResultQuantitative myocardial blood flow with Rubidium-82 PET: a clinical perspective.
Hagemann, C. A., Ghotbi, A. A., Kjær, A., & Hasbak, P. (2015) · Europe PMC (PubMed Central) · Cited by 33
Outcomes of Participants With Diabetes in the ISCHEMIA Trials
Newman, J. D., Anthopolos, R., Mancini, G. B. J., Bangalore, S., Reynolds, H. R., Kunichoff, D. F., Senior, R., Peteiro, J., Bhargava, B., Garg, P., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054439 · Cited by 35
Self-citationPredictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial
Senior, R., Reynolds, H. R., Min, J. K., Berman, D. S., Picard, M. H., CHAITMAN, B. R., Shaw, L. J., Page, C. B., Govindan, S. C., Lopez-Sendon, J. L., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.052 · Cited by 34
Self-citationNazir, M. S., Bustin, A., Hajhosseiny, R., Yazdani, M. F., Ryan, M. J., Vergani, V., Neji, R., Kunze, K., Nicol, E. D., Masci, P. G., et al. (2022) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-022-00858-0 · Cited by 35
“The assessment of CAD is important for patients so that appropriate medical therapy can be initiated, adverse clinical outcomes can be prevented and revascularization considered for relief of angina symptoms [29].”
BackgroundAssociation of Smoking Status With Health-Related Outcomes After Percutaneous Coronary Intervention
Jang, J., Buchanan, D. M., GOSCH, K. L., Jones, P. G., Sharma, P. K., Shafiq, A., Grodzinsky, A., Fendler, T. J., Graham, G. N., & Spertus, J. A. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002226 · Cited by 36
Self-citationAngina pectoris in women: Focus on microvascular disease
Zuchi, C., Tritto, I., & Ambrosio, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.07.001 · Cited by 35
“More extensive use of revascularization procedures, however, may reduce the burden of ischemic symptoms in women only to some extent, since: a) PCI or CABG do not eradicate symptoms in many such patients, as a sizable number of women remain symptomatic in spite of successful revascularization [57–60]; b) as already po…”
BackgroundFarhan, S., Járai, R., Tentzeris, I., Kautzky‐Willer, A., Samaha, E., Smetana, P., Jakl, G., Wojta, J., & Huber, K. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0435-3 · Cited by 38
Razzouk, L., Muntner, P., Bansilal, S., Kini, A. S., Aneja, A., Mozes, J. I., Ivan, O. C., Jakkula, M., Sharma, S., & Farkouh, M. E. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.026 · Cited by 36
Valgimigli, M., & Biscaglia, S. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0422-4 · Cited by 39
Tanaka, A., Tearney, G. J., & Bouma, B. E. (2010) · Journal of Biomedical Optics · doi:10.1117/1.3290810 · Cited by 33
Pakkal, M., Raj, V. J., & McCann, G. P. (2011) · British Journal of Radiology · doi:10.1259/bjr/50903757 · Cited by 38
“The COURAGE (Clinical Outcomes Utilizing Revascularization and AGgressive drug Evaluation) trial showed that in stable CAD with more than 70% stenosis, the adverse event rate (defined as all-cause mortality, non-fatal myocardial infarction, stroke and hospitalisation for acute coronary syndrome) was similar in patient…”
MethodComputed tomographic angiography or conventional coronary angiography in therapeutic decision-making
Piers, L. H., Dikkers, R., Willems, T. P., de Smet, B. J. G. L., Oudkerk, M., Zijlstra, F., & Tio, R. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn454 · Cited by 33
Cavender, M. A., Alexander, K. P., Broderick, S., Shaw, L. K., McCants, C. B., Kempf, J., & Ohman, E. M. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.10.013 · Cited by 33
Self-citationFoley, J. R., Plein, S., & Greenwood, J. P. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.92 · Cited by 33
Comparative Effectiveness Research: What Kind of Studies Do We Need?
Concato, J., Peduzzi, P. N., Huang, G. D., O’Leary, T. J., & Kupersmith, J. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181e3d2af · Cited by 76
“In other situations, this concern is not applicableYfor example, when VA studies are done in collaboration with the National Institutes of Health(49) or as international collaborations.(34) Overall, if examined as a body of knowledge, VA studies in CER have been considered reliable and relevant in improving care deliv…”
BackgroundSavarese, G., Rosano, G. M. C., D’Amore, C., Musella, F., Ratta, G. L. D., Pellegrino, A. M., Formisano, T., Vitagliano, A., Cirillo, A., Cice, G., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.131 · Cited by 32
Nallamothu, B. K., Tommaso, C. L., Anderson, H. V., Anderson, J. L., Cleveland, J. C., Dudley, R. A., Duffy, P. L., Faxon, D. P., Gurm, H. S., Hamilton, L. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.003 · Cited by 35
“symptom reduction, and data on a mortality rate benefit for this group are limited (14-16).”
BackgroundTargeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?
Larach, D. B., deGoma, E. M., & Rader, D. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0317-3 · Cited by 33
“Despite aggressive LDL-reducing therapy, there remains substantial residual cardiovascular risk [1, 2].”
Mancini, G. B. J., Hartigan, P. M., Bates, E., CHAITMAN, B. R., Sedlis, S. P., Maron, D. J., Kostuk, W. J., Spertus, J. A., Teo, K. K., Dada, M. R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.007 · Cited by 33
Self-citationThe Anti-Ischemic and Anti-Anginal Properties of Statins
Lardizabal, J. A., & DEEDWANIA, P. C. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0147-y · Cited by 34
Farooq, V., Vranckx, P., Mauri, L., Cutlip, D. E., Belardi, J., Silber, S., Widimský, P., Leon, M. B., Windecker, S., Meredith, I. T., et al. (2013) · Heart · doi:10.1136/heartjnl-2012-303368 · Cited by 32
Lorenzo, C. D., Paciello, R., Riccio, G., Rea, D., Barbieri, A., Coppola, C., & Maurea, N. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s157294 · Cited by 32
Pezel, T., Sanguineti, F., Kinnel, M., Hovasse, T., Garot, P., Unterseeh, T., Champagne, S., Louvard, Y., Morice, M., & Garot, J. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa193 · Cited by 32
Dyrbuś, K., Gąsior, M., Desperak, P., Trzeciak, P., Nowak, J. U., Penson, P. E., Osadnik, T., & Banach, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.024 · Cited by 33
“The occurrence of MI is associated with substantially worse outcomes than other manifestations of CVD [10,11].”
BackgroundNew drugs vs. old concepts: A fresh look at antiarrhythmics
Thireau, J., Pasquié, J., Martel, E., Guennec, J. L., & Richard, S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.003 · Cited by 35
“Dronedarone is a derivative of amiodarone that is expected to be devoid of most of its adverse side-effects, particularly on thyroid function (Boden et al., 2007).”
BackgroundFeringa, H. H. H., Karagiannis, S. E., Vidaković, R., Elhendy, A. A., ten Cate, F. J., Noordzij, P. G., van Domburg, R. T., Bax, J. J., & Poldermans, D. (2007) · Coronary Artery Disease · doi:10.1097/mca.0b013e3282f08e86 · Cited by 39
Jeon, C., Candia, S. C., Wang, J. C., Holper, E. M., Ammerer, M., Kuntz, R. E., & Mauri, L. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.004 · Cited by 32
Management of Coronary Artery Calcium and Coronary CTA Findings
Thomas, D. M., Divakaran, S., Villines, T. C., Nasir, K., Shah, N. R., Slim, A. M., Blankstein, R., & Cheezum, M. K. (2015) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-015-9334-0 · Cited by 34
“Indeed, no survival advantage was seen in either the BARI-2D or COURAGE trials among patients with obstructive CAD undergoing revascularization compared with medical therapy alone [76, 77].”
MethodTreatment with Cardiotonic Pills® after Ischemia‐Reperfusion Ameliorates Myocardial Fibrosis in Rats
Wei, X., Liu, Y., Li, Q., Yan, L., Hu, B., Pan, C., Li, Z., Chang, X., Fan, J., Zhao, N., et al. (2012) · Microcirculation · doi:10.1111/micc.12002 · Cited by 32
“Interventional therapies have currently been applied widely to salvage patients’ lives to some extent, but they do not reduce the risk of death [1].”
Background
Metadata
- Authors
- Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G. B. J., & Weintraub, W. S.
- Affiliations
- VA Western New York Healthcare System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1503-1516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160414137
- Cited by
- 4,699
- References
- 49
- Citations by year
- 2026: 111 · 2025: 142 · 2024: 150 · 2023: 166 · 2022: 197 · 2021: 255 · 2020: 282 · 2019: 202 · 2018: 227 · 2017: 211 · 2016: 276 · 2015: 263 · 2014: 295 · 2013: 309 · 2012: 322
- FWCI
- 315.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- optimal medical therapy, percutaneous coronary intervention, stable coronary artery disease, myocardial ischemia, cardiovascular events, myocardial infarction, mortality, lifestyle intervention, coronary artery disease
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Anticholesteremic Agents, Antihypertensive Agents, Combined Modality Therapy, Coronary Disease, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk Factors, Angioplasty, Balloon, Coronary, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.